Skip to main content

Table 2 Details of patient characteristics, results of each PET imaging, and reference criteria for the final diagnosis in patients with non-glioma tumors and non-neoplastic lesions

From: Diagnostic accuracy of 13N-ammonia PET, 11C-methionine PET and 18F-fluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma

Pt. No.

Age range (y)

Locationa

FDG

NH3

MET

Method of diagnosis

Final diagnosis

Visual

L/WMb

Visual

L/WM

Visual

L/WM

Non-glioma tumors

 1

50–55

Cerebellum

(+)

2.24

(+)

1.72

(+)

2.89

Operation

Metastatic adenocarcinoma

 2

20–25

L. basal ganglia region

(−)

1.32

(+)

2.67

(+)

3.24

Biopsy

Germinoma

 3

35–40

R. cavernous sinus area

(+)

2.38

(+)

2.30

(+)

3.35

Operation

Squamous cell carcinoma

 4

40–45

Suprasellar

(−)

1.07

(+)

2.42

(+)

2.28

Operation

Craniopharyngioma

 5

65–70

R. parietal

(−)

1.37

(+)

3.75

(+)

2.72

Operation

Meningioma

 6

60–65

Cerebellum

(−)

1.28

(+)

3.66

(+)

2.78

Operation

Hemangioblastoma

 7

25–30

Cerebellum

(+)

2.61

(+)

2.00

(+)

2.00

Operation

Medulloblastoma

 8

25–30

Cerebellum

(+)

2.32

(+)

2.40

(+)

2.24

Operation

Medulloblastoma

 9

45–50

L. frontal

(+)

4.02

(+)

3.09

(+)

3.00

Operation

Metastatic tumor

 10

30–35

R. frontal

(−)

1.22

(−)

1.60

(+−)

1.51

Operation

DNT

Non-neoplastic lesions

 11

20–25

L. frontal

(+)

2.75

(+−)

1.68

(+−)

1.58

Follow-up

Inflammation

 12

40–45

L. frontal-parietal

(−)

1.76

(−)

1.10

(−)

1.00

Biopsy

Demyelination

 13

30–35

R. parietal

(+−)

2.10

(+−)

1.64

(+)

2.27

Follow-up

Demyelination

 14

25–30

R. basal ganglia region

(+−)

2.12

(+−)

1.72

(+−)

1.50

Biopsy

Demyelination

 15

70–75

Cervical spinal

(+)

2.88

(+−)

1.70

(+−)

1.78

Follow-up

Inflammation

 16

20–25

R. cerebellopontine angle

(−)

1.32

(+−)

1.63

(+−)

1.55

Follow-up

Demyelination

 17

25–30

R. thalamus

(−)

1.80

(+−)

1.75

(+−)

1.77

Follow-up

Inflammation

 18

40–45

R. parietal

(+)

2.23

(+−)

1.72

(+)

2.49

Biopsy

Inflammation

 19

35–40

R. cerebellum

(+)

2.80

(−)

1.45

(−)

1.38

Follow-up

Inflammation

 20

40–45

Brain stem, R. temporal

(−)

1.58

(−)

1.55

(+−)

1.54

Follow-up

Inflammation

 21

40–45

L. pons

(−)

1.56

(−)

1.29

(−)

1.31

Follow-up

Infarction

 22

50–55

L. temporal

(+)

2.49

(−)

0.94

(+)

2.67

Operation

Brain abscess

 23

45–50

L. parietal

(+)

3.28

(−)

1.63

(+)

2.88

Operation

Brain abscess

 24

40–45

R. frontal

(+)

3.80

(−)

1.58

(+)

3.04

Operation

Brain abscess

 25

20–25

L. parietal

(−)

1.10

(−)

1.18

(−)

1.32

Biopsy

Demyelination

 26

30–35

L. basal ganglia region

(−)

1.44

(−)

1.45

(−)

1.40

Follow-up

Multiple sclerosis

 27

40–45

R. cerebellum

(−)

1.98

(+−)

1.79

(+)

2.60

Follow-up

Infarction

 28

50–55

L. frontal

(+−)

2.10

(+−)

1.75

(+)

1.95

Biopsy

Inflammation

 29

78–80

R. parietal

(−)

1.06

(−)

1.14

(+)

1.86

Follow-up

Hemorrhage

 30

40–45

L. frontal and parietal

(+)

2.70

(+)

1.87

(+)

3.15

Biopsy

Inflammation

 31

40–45

Pons

(−)

1.68

(−)

1.54

(−)

1.38

Follow-up

Brain abscess

 32

50–55

R. basal ganglia region

(−)

1.58

(−)

1.02

(+)

1.81

Follow-up

Infarction

 33

25–30

L. thalamus

(−)

1.52

(−)

1.44

(−)

1.15

Biopsy

Demyelination

  1. a R right, L left, b L/WM Lesion-to-white matte ratio, DNT dysembryoplastic neuroepithelial tumor